OBIO CAAP Company: Mariner Endosurgery Receives Health Canada Investigational Testing Approval for LaparoGuard Technology

Mariner Endosurgery Inc., an innovative Canadian medical device company leading commercialization of computer-assisted medical devices for laparoscopic surgeries, announced today that it has received Investigational Testing Approval (ITA) from Health Canada.  Receipt of the ITA enables the company to initiate clinical testing of Mariner’s LaparoGuard computer-assisted surgery platform which is planned to begin February 2018 at Hamilton General Hospital.  Dr. Niv Sne, trauma surgeon proficient in advanced laparoscopic cases with Hamilton Health Sciences and Associate Professor of Surgery at McMaster University is the principal investigator for the initial studies.

The receipt of Investigational Testing Approval for LaparoGuard computer-assisted surgery represents an important step in advancing an exciting new technology that we believe offers great promise in mitigating risk and improving confidence by enhancing visualization for surgeons.
— Dr. David Langlois, Chief Medical Officer, & Mariner Endosurgery
Previous
Previous

OBIO CAAP Company: Flosonics Medical Secures $5 Million Seed Round Funding

Next
Next

CAAP Company: Self Care Catalysts awarded IDC Innovator